Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2949448 | 0.84 | ALDH1A1 (0.55) | MCL1CA1CA2PTGS2CA12 | |
| SCHEMBL29623237 | 0.83 | MCL1 (0.71) | MCL1CA1CA2PTGS2CA12 | |
| SCHEMBL341888 | 0.83 | MCL1 (0.71) | MCL1CA1CA2PTGS2CA12 | |
| SCHEMBL739200 | 0.83 | MCL1 (0.71) | MCL1CA1CA2PTGS2CA12 | |
| SCHEMBL6715410 | 0.82 | MCL1 (0.69) | MCL1CA1CA2PTGS2CA12 | |
| SCHEMBL27854523 | 0.80 | MCL1 (0.67) | MCL1CA1CA2PTGS2CA12 | |
| SCHEMBL11449962 | 0.80 | MCL1 (0.67) | MCL1CA1CA2PTGS2CA12 | |
| SCHEMBL3187695 | 0.80 | MCL1 (1.00) | MCL1CA1CA2PTGS2CA12 | |
| SCHEMBL6401695 | 0.80 | MCL1 (0.67) | MCL1CA1CA2PTGS2CA12 | |
| SCHEMBL9367905 | 0.79 | MCL1 (0.61) | MCL1CA1CA2PTGS2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119237-A1 | Non-malignant disease treatment with Ras antagonists | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. (IL) | 2005-06-02 | — | — | US | disclosed |
| EP-1187605-A4 | NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | THYREOS CORP (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6462086-B1 | SUCH AS FARNESYLTHIOSALICYLIC ACID; INHIBITING PROLIFERATION OF T-CELLS; DIABETES, LUPUS, MULTIPLE SCLEROSIS; GRAFT REJECTION INDUCED BY FOREIGN ANTIGENS; CIRRHOSIS, RESTENOSIS | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 2002-10-08 | — | — | US | disclosed |
| EP-1187605-A1 | NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | Thyreos Corporation (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078303-A1 | NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | THYREOS CORPORATION (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119237-A1 | Non-malignant disease treatment with Ras antagonists | RSU1, KSR1, KRAS | MCL1 140/4885CA1 3526/4885CA2 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.